Hodgkin Building
Guy's Campus
London
SE1 1UL
+44(0)207.848.6938
+44(0)207.848.6034
James Hunter
Proximagen Neuroscience plc is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease. Proximagen is building a compound pipeline to address the significant unmet medical needs of patients with neurodegenerative disease through its own discovery programme for novel, low risk therapeutic candidates, and through the identification and licensing of existing drugs for new indications.
| Description | Report Date | Published |
|---|---|---|
| Annual Report 2009 | 30-11-2009 | 31-03-2010 |
| Annual Report 2008 | 30-11-2008 | 23-03-2009 |
| Annual Report 2007 | 30-11-2007 | 03-04-2008 |
| Annual Report 2006 | 30-11-2006 | 27-02-2007 |
| Annual Report 2005 | 30-11-2005 | 26-05-2006 |
| Description | Report Date | Published |
|---|---|---|
| Interim Report 2009 | 31-05-2009 | 23-07-2009 |
| Interim Report 2008 | 31-05-2008 | 13-08-2008 |
| Interim Report 2007 | 31-05-2007 | 29-08-2007 |
| Interim Report 2006 | 31-05-2006 | 19-07-2006 |
| Description |
|---|
| Investor Relations |
| Home |
| Press Releases |
| Contacts |
| Type | Dividend | Payment Date |
|---|---|---|
| Nil | 0.0000 | 09-05-2006 |